Patient Leaflet Updated 18-Aug-2026 | Aurobindo Pharma - Milpharm Ltd.
Montelukast 4 mg chewable tablets
Montelukast 4 mg
chewable tablets
montelukast
1. What Montelukast is and what it is used for
2. What you need to know before you take Montelukast
3. How to take Montelukast
4. Possible side effects
5. How to store Montelukast
6. Contents of the pack and other information
Montelukast is a leukotriene receptor antagonist that blocks substances called leukotrienes.
Leukotrienes cause narrowing and swelling of airways in the lungs. By blocking leukotrienes, Montelukast improves asthma symptoms and helps control asthma.
Your doctor has prescribed Montelukast to treat your child’s asthma, preventing asthma symptoms during the day and night.
Your doctor will determine how Montelukast should be used depending on the symptoms and severity of your child’s asthma.
Asthma is a long-term disease.
Asthma includes:
Symptoms of asthma include: Coughing, wheezing, and chest tightness.
Tell your doctor about any medical problems or allergies your child has now or has had.
Talk to your doctor or pharmacist before you give Montelukast to your child.
Various neuropsychiatric events (for example behaviour and mood-related changes, depression and suicidality) have been reported in patients of all ages treated with montelukast (see section 4). There have also been reports of these symptoms continuing after treatment is stopped. If you develop such symptoms while taking montelukast or if these symptoms do not resolve after montelukast is stopped, you should contact your prescriber.
Do not give this medicine to children less than 2 years of age.
There are different form(s) of this medicine available for paediatric patients under 18 years of age based on age range.
Tell your doctor or pharmacist if your child is taking or has recently been given or might be given any other medicines including those obtained without a prescription.
Some medicines may affect how Montelukast works, or Montelukast may affect how your child’s other medicines work.
Tell your doctor if your child is taking the following medicines before starting Montelukast:
Montelukast 4 mg chewable tablets should not be taken immediately with food; they should be taken at least 1 hour before or two hours after food.
This subsection is not applicable for the Montelukast chewable tablets since they are intended for use in children 2 to 5 years of age.
This subsection is not applicable for the Montelukast 4 mg chewable tablets since they are intended for use in children 2 to 5 years of age, however the following information is relevant to the active ingredient, montelukast.
Montelukast is not expected to affect your ability to drive a car or operate machinery. However, individual responses to medication may vary.
Certain side effects (such as dizziness and drowsiness) that have been reported very rarely with Montelukast may affect some patients’ ability to drive or operate machinery.
Montelukast contain aspartame, a source of phenylalanine. If your child has phenylketonuria (a rare, hereditary disorder of the metabolism) you should take into account that each Montelukast 4 mg chewable tablet contains phenylalanine (equivalent to 0.674 mg phenylalanine per 4 mg chewable tablet).
This medicine contains less than 1 mmol sodium (23 mg) per each tablet, that is to say essentially ‘sodium-free’.
Always have your child take this medicine exactly as your doctor or pharmacist has told you. Check with your child’s doctor or pharmacist if you are not sure.
The recommended dose is one 4 mg chewable tablet daily to be taken in the evening.
If your child is taking Montelukast, be sure that he/she does not take any other medicines that contain the same active ingredient, montelukast.
This medicine is for oral use.
The tablets are to be chewed before swallowing.
Montelukast 4 mg chewable tablets should not be taken immediately with food; it should be taken at least 1 hour before or 2 hours after food.
Contact your child’s doctor immediately for advice.
There were no side effects reported in the majority of overdose reports. The most frequently occurring symptoms reported with overdose in adults and children included abdominal pain, sleepiness, thirst, headache, vomiting, and hyperactivity.
Try to give Montelukast as prescribed. However, if your child misses a dose, just resume the usual schedule of one tablet once daily.
Do not give a double dose to make up for a forgotten dose.
Montelukast can treat your child’s asthma only if your child continues taking it.
It is important for your child to continue taking Montelukast for as long as your doctor prescribes.
It will help control your child’s asthma.
If you have any further questions on the use of this product, ask your child’s doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
In clinical studies with montelukast 4 mg chewable tablets, the most commonly reported side effects (may affect up to 1 in 10 people) thought to be related to montelukast were:
Additionally, the following side effect was reported in clinical studies with montelukast 10 mg film-coated tablets and 5 mg chewable tablets:
These were usually mild and occurred at a greater frequency in patients treated with montelukast than placebo (a pill containing no medication).
Talk with your doctor immediately if you notice any of the following side effects, which may be serious, and for which you may need urgent medical treatment.
Uncommon: the following may affect up to 1 in 100 people
Rare: the following may affect up to 1 in 1,000 people
Very rare: the following may affect up to 1 in 10,000 people
Very common: the following may affect more than 1 in 10 people
Common: the following may affect up to 1 in 10 people
Uncommon: the following may affect up to 1 in 100 people
Rare: the following may affect up to 1 in 1,000 people
Very rare: the following may affect up to 1 in 10,000 people
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated after ‘EXP’ on the blister and carton.
The expiry date refers to the last day of that month.
Store below 25ºC.
Store in the original package in order to protect from light and moisture.
[HDPE bottle of 500 tablets]
Use within 12 months after first opening the HDPE bottle.
Do not throw away any medicine via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
Chewable tablets
Pink coloured, mottled, oval, biconvex, uncoated tablets debossed with ‘X’ on one side and ‘52’ on other side.
Montelukast chewable tablets are available in PVC/ Polyamide/ Aluminium foil/ PVC blister pack and HDPE bottle with polypropylene closure containing silica gel desiccant.
Presentations
Blister pack: 7, 10, 14, 20, 28, 30, 49, 50, 56, 60, 84, 90, 98, 100, 140 and 200 chewable tablets.
HDPE bottle pack: 30, 90 and 500 chewable tablets
Not all pack sizes may be marketed.
or
This leaflet was last revised in 06/2026.
Ref Ver: 01
P1542814
Milpharm Limited, 1 Roundwood Avenue, Stockley Park, Uxbridge, UB11 1AF, UK
+ 44 (0)208 845 8811
+44 (0)208 845 8811
http://www.aurobindo.com
+44 (0)208 845 8795